News
Mirdametinib is marketed under the brand name EZMEKLY ® in the European Union and is conditionally approved by the European Commission (EC) for the treatment of symptomatic, inoperable plexiform ...
The FDA has approved Kerendia® (finerenone) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.
“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...
The White House says President Trump underwent a medical exam because of swelling in his legs and has been diagnosed with a ...
With the launch, Anumana became the first organization to utilize the marketplace. Philips now plans to make offer the ...
NewYork-Presbyterian researchers have developed a deep learning model that increases doctors' abilities to diagnose ...
Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...
The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...
A new study shows that people with a type of heart failure called HFpEF (heart failure with preserved ejection fraction) are ...
2d
Medical Device Network on MSNFDA grants 510(k) clearance for Tempus AI’s ejection fraction softwareThe US Food and Drug Administration (FDA) has granted 510 (k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software. This software utilises AI to detect individuals with a low left ...
The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results